Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review.

Authors: Mansour GK, Altebainawi AF, Hajjar AW, Sayed SBH, Alazem FA, Sajid MR.

DOI: 10.3390/jcm14238594

Abstract Summary

Mavacamten represents a breakthrough in treating hypertrophic cardiomyopathy (HCM), the most common inherited heart disease. Unlike traditional therapies that only manage symptoms, this first-in-class drug directly targets the root cause—overactive heart muscle contractions. Clinical trials show it reduces obstruction, improves heart function, and enhances patients’ quality of life, marking a shift from symptom control to actual disease modification.

Why Brain? 🧠

Mavacamten is the first drug to directly target the root cause of obstructive hypertrophic cardiomyopathy by reducing excessive heart muscle contraction, showing sustained safety and efficacy beyond symptom relief.

License: cc by.

The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.